Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00721123 · OUTCOME

Change From Baseline in Scores for Patient's Global Assessment of Disease Activity Over Time, Through 264 Weeks

A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis · Source last updated 2013-11-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Units on a Scale
Interval / dispersion
Standard Deviation
Time frame
through 264 Weeks

What was measured

Patient's global assessment of disease activity is the patient's overall assessment of their disease activity during specified time periods on a 100 mm horizontal visual analogue scale (VAS). The left-hand extreme of the line was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme as "maximum disease activity" (maximum arthritis disease activity). Change from baseline was calculated for given periods, and a negative change indicates improvement.

Analysis population: All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.

Groups in this outcome

Week 24

Participants with scores at 24 weeks post-baseline.

Week 48

Participants with scores at 48 weeks post-baseline.

Week 108

Participants with scores at 108 weeks post-baseline.

Week 156

Participants with scores at 156 weeks post-baseline.

Week 204

Participants with scores at 204 weeks post-baseline.

Week 264

Participants with scores at 264 weeks post-baseline.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Week 24521
Week 48479
Week 108442
Week 156414
Week 204387
Week 264367

Reported measurements

Source class 1
Values in Units on a Scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Week 24-26.626.87Not reportedNot reportedNot reported
Week 48-30.327.71Not reportedNot reportedNot reported
Week 108-31.127.65Not reportedNot reportedNot reported
Week 156-31.626.74Not reportedNot reportedNot reported
Week 204-33.026.83Not reportedNot reportedNot reported
Week 264-32.927.58Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        26.87
        value
        -26.6
      2. group Id
        OG001
        spread
        27.71
        value
        -30.3
      3. group Id
        OG002
        spread
        27.65
        value
        -31.1
      4. group Id
        OG003
        spread
        26.74
        value
        -31.6
      5. group Id
        OG004
        spread
        26.83
        value
        -33.0
      6. group Id
        OG005
        spread
        27.58
        value
        -32.9
denoms
  1. counts
    1. group Id
      OG000
      value
      521
    2. group Id
      OG001
      value
      479
    3. group Id
      OG002
      value
      442
    4. group Id
      OG003
      value
      414
    5. group Id
      OG004
      value
      387
    6. group Id
      OG005
      value
      367
    units
    Participants
description
Patient's global assessment of disease activity is the patient's overall assessment of their disease activity during specified time periods on a 100 mm horizontal visual analogue scale (VAS). The left-hand extreme of the line was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme as "maximum disease activity" (maximum arthritis disease activity). Change from baseline was calculated for given periods, and a negative change indicates improvement.
dispersion Type
Standard Deviation
groups
  1. description
    Participants with scores at 24 weeks post-baseline.
    id
    OG000
    title
    Week 24
  2. description
    Participants with scores at 48 weeks post-baseline.
    id
    OG001
    title
    Week 48
  3. description
    Participants with scores at 108 weeks post-baseline.
    id
    OG002
    title
    Week 108
  4. description
    Participants with scores at 156 weeks post-baseline.
    id
    OG003
    title
    Week 156
  5. description
    Participants with scores at 204 weeks post-baseline.
    id
    OG004
    title
    Week 204
  6. description
    Participants with scores at 264 weeks post-baseline.
    id
    OG005
    title
    Week 264
param Type
MEAN
population Description
All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.
reporting Status
POSTED
time Frame
through 264 Weeks
title
Change From Baseline in Scores for Patient's Global Assessment of Disease Activity Over Time, Through 264 Weeks
type
SECONDARY
unit Of Measure
Units on a Scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice